TON - Other published on May 9, 2011 in Conference Correspondent

ACOSOG Z1031: Neoadjuvant Comparison between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor–Rich Stage 2/3 Breast Cancer

TON - Other published on May 6, 2011 in Conference Correspondent

ZETA: Vandetanib in Locally Advanced or Metastatic Medullary Thyroid Cancer

TON - Other published on May 6, 2011 in Conference Correspondent

Impaired Hydroxylation of 5-Methylcytosine in TET2-Mutated Myeloid Malignancies

TON - Other published on December 21, 2011 in Survivorship

There is a lack of guidelines when it comes to standard of care for adult cancer survivors, and it is time to start thinking about establishing such guidelines, according to nurse practitioner Richard Boyajian, who is the clinical director of adult survivorship at Dana-Farber Cancer Institute, Boston, Massachusetts. He said establishing appropriate guidelines could potentially reduce morbidity and mortality.

TON - Other published on May 9, 2011 in Drug Updates & News

TON - Other published on August 23, 2012 in Reader Survey

In the July issue, we published an article exploring the efforts to deal with the drug shortage issue. We asked our online reading community if they thought these regulatory and legislative actions would be effective.

  • 38% said they thought the recent actions would help resolve the issue
  • 62% indicated they were not confident that recent actions would be effective

Here’s a sample of the comments:

TON - Other published on April 12, 2011 in Navigation

For the up to two-thirds of men with azoospermia after chemotherapy, microdissection testicular sperm extraction (TESE) and intracytoplasmic sperm injection (ICSI) can salvage fertility, according to the largest reported series of postchemotherapy microdissection TESE-ICI to date. Although prechemotherapy sperm banking remains a recommended part of any treatment plan, researchers from Weill Cornell Medical College in New York City demonstrated that assisted reproductive techniques should be offered to patients who did not preserve sperm.

TON - Other published on January 3, 2012

The US Food and Drug Administration (FDA) has approved a supplemental new drug application for Velcade (bor tezomib) for Injection (Millennium: The Takeda Oncology Company) that updates the label to include additional longterm (median follow-up 60.1 months) overall survival (OS) data from the VISTA trial. The VISTA trial examined the use of bortezomib-based therapy in patients with previously untreated multiple myeloma (MM).

TON - Other published on February 15, 2013
Most of the illnesses that are encountered in medicine are incurable. Diabetes and heart disease are 2 of the common, chronic, and incurable health conditions that require diligent monitoring.
TON - Other published on February 15, 2013
Novel therapies for patients with multiple myeloma (MM) continue to show improved outcomes for a population that as little as 8 years ago had few options.
Page 1 of 7
Results 1 - 10 of 63